← All trials
NCT04187872
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2020
- Primary completion
- Jan 31, 2022
- Completion date
- Oct 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of FloridaLead sponsor
- University of FloridaOverall official - principal investigator
- Monteris MedicalCollaborator
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Carcinoma, Hepatocellular
- Hodgkin Disease
- Melanoma
- Neoplasm Metastasis
- Neoplasms
- Stomach Neoplasms
- Carcinoma, Merkel Cell
- Lymphoma, Large-Cell, Immunoblastic
- Small Cell Lung Carcinoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.